Background: Nocturnal gastroesophageal reflux (nGER) has received increasing interest as a predisposing factor for respiratory diseases and sleep disturbances. The possible role of obstructive sleep apnea (OSA) contributing to nGER is of special interest. The aim of this study was to explore the association between nGER and respiratory diseases, lung function and symptoms of OSA. Methods: Participants in the Burden of Obstructive Lung Disease (BOLD) initiative in Iceland and Sweden, a random sample from the general population of 1325 adults aged 40þ (>70% response rate), were compared by pre-and post-bronchodilator spirometry, answers to questionnaires about OSA and respiratory symptoms, health, and symptoms of GER. Results: Altogether 102 (7.7%) reported nGER and 249 had used medication against GER. The participants were divided into three groups: 1) No nGER (n Z 1040), 2) treated GER without nGER (n Z 183) and 3) nGER (n Z 102). The nGER group had a significantly higher prevalence of respiratory and OSA symptoms than subjects without nGER. The nGER group also had a higher prevalence of COPD (GOLD stage 1þ), (25.0% vs. 15.6%) (p Z 0.02) and lower FEV 1 /FVC ratio (95.9% vs. 98.9% of the predicted, p Z 0.01). These associations remained significant after adjusting for smoking, weight and other possible confounders. No independent association was found between having treated GER and lung function, respiratory or OSA symptoms.
Introduction
Gastroesophageal reflux (GER) is a common condition, the cardinal symptoms being heartburn and regurgitation. 1, 2 Prevalence numbers vary from 7 to 40%. 1,3e5 Various respiratory symptoms and conditions have been shown to co-occur with GER, such as wheeze, rales, cough or phlegm. 1, 5 The association between GER and lung function in the general population, however, has only been studied to a small degree, and it is therefore unclear if GER has any long term consequences on lung function. A study published in 2010 showed that patients with recently diagnosed GER disease had significantly lower forced expiratory volume in 1 s (FEV 1 ) and peak expiratory flow (PEF) than a control group. 6 Both respiratory symptoms and obstructive sleep apnea (OSA) have been shown to concur with GER even in a vicious circle as OSA can increase the risk for nGER and vice versa. 7, 3 In this context, nocturnal GER (nGER) has been of special interest. 8 In our previous study on young adults with nGER, both respiratory and OSA symptoms were increased among nGER subjects. 9 Also, treatment of OSA with nasal continuous positive airway pressure (CPAP) has shown to improve nGER. 10, 11 Many theories have been put forth about what causes nGER in OSA patients, from repeated increases in negative intrathoracic pressure, to transient lower esophageal sphincter relaxation. 12e14 However, the nature of this association is still not thoroughly understood. 14, 15 Further studies are needed to clarify the nature of respiratory symptoms in patients with nGER and comorbid OSA. 16 The aim of this investigation was to study nGER in adults 40 years and older and its association to postbronchodilatory lung function, respiratory symptoms and OSA-related symptoms in two Northern European centers.
Material and methods

Study population
The study population was primarily invited to participate in The Burden of Obstructive Lung Diseases (BOLD) initiative in Iceland and Sweden, a multicentre international study aiming to estimate the burden of COPD worldwide. 17 The present analyses are based on data from Reykjavik, Iceland, and Uppsala, Sweden, that has been described before. 18 Briefly, using the national registries of inhabitants in both countries, a random sample of adults aged 40 and over was contacted and invited to participate in an examination that included a structured interview, medical examination, blood sample and a spirometry. The study was approved by the local ethics committees (National Bioethics Committee of Iceland: 04-080; Swedish Research Council: 2006/146).
Data collected and definitions
Questionnaires As a part of the BOLD study protocol, all participants came to the outpatient clinic of the respective hospitals in Uppsala and Reykjavik where they answered equivalent questionnaires on GER, symptoms of OSA, the Epworth sleepiness scale, respiratory symptoms, smoking, health status, medication use and other health related issues. 17e19 The questionnaires had in previous studies been translated from English into Icelandic and Swedish, and then backtranslated to check for accuracy. Trained and certified staff administered the questionnaire.
Gastroesophageal reflux
Participants reporting heartburn once a week or more after going to bed were considered to have nGER. 9 Those reporting use of medication against heartburn during the preceding three months were defined as having GER treatment. Based on these data the participants were categorized into three groups: (a) No nGER and no GER treatment, called "No nGER"; (b) GER treatment but no nGER, called "Treated GER"; (c) nGER with or without GER treatment, called "nGER".
Diabetes, hypertension and body mass index
The participants were defined as having hypertension or diabetes if they reported doctor-diagnosed hypertension or diabetes and were using appropriate medication. Height and weight were measured by standardized methods. Body mass index (BMI) was calculated as weight divided by squared height.
Respiratory and OSA-related symptoms
The participants were asked whether they had experienced a number of respiratory symptoms such as cough, phlegm 1) How does this advance the field?
This epidemiological study increases the awareness of the evident association between nocturnal gastroesophageal reflux (nGER) and respiratory symptoms and diseases, as well as obstructive sleep apnea (OSA). There is also evidence that nGER negatively affects lung function, which has only been vaguely reported before. 2) What are the clinical implications?
Attention must be given to nGER in patients with respiratory symptoms and illnesses and the possibility of OSA evaluated. As symptoms of OSA are more common among nGER patients, OSA needs to be assessed in these patients. Successful treatment of nGER seems to diminish the negative respiratory outcomes. and wheeze. 17 The questionnaire also included questions on smoking history, by which participants were divided into smokers, ex-smokers and never-smokers. The OSA-related questions included self-reported snoring, apneas, daytime sleepiness and the Epworth sleepiness scale. 18 Those reporting either coughing most days for up to three months each year, having phlegm most days for up to three months each year, any wheeze for the last 12 months or shortness of breath when hurrying were classified as having "any respiratory symptom". Those with observed snoring or daytime sleepiness more than twice a week, or with observed apneas once a week or more, were classified as having "any OSA symptom".
Spirometry
Trained and certified technicians performed spirometry according to ATS criteria 17 (EasyOne spirometer; ndd Medizintechnik; Zurich, Switzerland) as described before. 20 Briefly, FEV 1 and forced vital capacity (FVC) values were obtained by spirometry. Pre-and post-bronchodilator tests were performed, with separate measurements performed before and after !15 min after two puffs of salbutamol (200 mg). The primary reference equations used by BOLD were derived from the third United States National Health and Nutrition Examination Survey (NHANES III) for adult Caucasian men and women. 21 COPD was defined by spirometry as a post-bronchodilatory FEV 1 /FVC < 0.70, 17 or as being below the age-adjusted lower limit of normality (LLN) in post-bronchodilatory FEV 1 /FVC. 21 Subjects with COPD were grouped into stages I to IV based on FEV 1 /FVC and FEV 1 . 22
Statistical analyses
All statistics were calculated with STATA 11.0 version intercooled for Windows (Stata Corporation, College Station, Texas). Associations between nGER status and symptoms were analyzed by a chi square test and logistic regression, while associations between nGER and continuous variables were analyzed with linear regression. Multiple logistic and linear regressions were used to estimate differences between the groups, adjust for center, age, gender, BMI and smoking history, and do interaction analyses. A p-value of <0.05 was defined as being statistically significant.
Results
Study groups' characteristics and prevalence of nGER
Of the 1325 subjects included in the analysis, 183 individuals were on GER medication and did not report nGER symptoms (13.8%), and 102 (7.7%) reported nGER, whereof 66 of them were on medication against GER (64.7%) ( Fig. 1 ). The three groups were comparable regarding age, gender and diabetes (Table 1 ). Hypertension and cigarette smoking were significantly more common in the GER treated group, and BMI was higher in that same group (Table 1) .
Respiratory and obstructive sleep apnea symptoms
Subjects with nGER had a higher prevalence of respiratory symptoms than subjects without GER ( Table 2 , Fig. 2 ). Symptoms of OSA were more common in the treated GER and nGER groups ( Table 2 , Fig. 2 ). The group with nGER had the highest ESS score, and the highest prevalence of daytime sleepiness and observed apneas of the three groups. The prevalence of snoring was highest in the nGER group, although not statistically significant. The association Figure 1 Venn diagram of subjects with GER treatment, nocturnal GER or both.
Symptoms of nGER, OSA and lung function: An epidemiological study between nGER and respiratory and OSA symptoms remained statically significant after adjustment for center, sex, age, BMI and smoking history ( Table 3) .
Lung function
COPD, as diagnosed by post-bronchodilator spirometry (FEV 1 /FVC < 0.70 or below LLN), 17, 20 was significantly more common in the group with nGER (Table 4 ). Subjects with treated GER had a significantly lower FEV 1 , while subjects with nGER had a significantly lower FEV 1 /FVC than subjects without GER ( Table 4 ). The association between treated GER and FEV 1 lost its statistical significance after adjusting for center, age, gender, smoking history and BMI, while the other associations remained significant ( Table 5 ).
Interactions
Interaction analyses were done while simultaneously adjusting for center, age, gender, smoking history and BMI. These analyses showed the association between nGER and OSA symptoms was stronger in subjects from Reykjavík than from Uppsala (OR (95% CI): 3.60 (1.86e7.00) vs. 1.42 (0.81e2.49), p interaction Z 0.04). Also, this same association was stronger among women than men (OR (95% CI): 3.55 (1.86e6.78) vs. 1.42 (0.80e2.51), p interaction Z 0.04).
There was a significant difference in the association between nGER and FEV 1 between subjects with a normal BMI (20e25) and obese subjects (>30), showing that among normal weight subjects, those with nGER had significantly lower FEV 1 than those without GER, while no significant association of this sort was found among obese subjects (coef. (95% CI): À8.10 (À14.51, À1.70) vs. 3.62 (À2.44, 9 .67), p interaction Z 0.01). Finally, the association between nGER and lower FEV 1 /FVC was stronger among men than women (coef. (95% CI): À5.67 (À8.52, À2.82) vs. À0.13 (À3.11, 2.85), p interaction Z 0.007).
No interactions were found in relation to smoking or age.
Discussion
The findings of this population-based study showed that nocturnal GER is associated with both respiratory and OSA symptoms. Nocturnal GER was also associated with a lower FEV 1 /FVC ratio and a significantly higher proportion fulfilling the spirometric criteria for COPD. These associations were much weaker in the treated GER group. The prevalence of nGER in the general population 40 years and older was almost 8%. In our previous study on young adults using the same criteria for nGER (age range 20e48 years), it was 4.6%, 9 which might suggest an increase in prevalence with increasing age. However, since the mean age was not different between subjects with or without nGER in either study, and no difference in nGER prevalence was found between age groups in the current study (data not shown), this rather suggests an increase in the overall prevalence of nGER from 1990 to 1993 to 2004e2006. A possible reason for this is the 3.5 points' higher average BMI in the current study population. Also, as 24.4% had a BMI above 30, high prevalence of obesity among people 40 years and older was a particularly worrying finding given the harmful association between BMI, nGER and the findings of our study.
A major finding of this study was the significantly lower FEV 1 /FVC ratio in subjects with nGER compared to the subjects without GER. Also, among normal weight subjects, those with nGER had a significantly lower FEV 1 than those without GER. This association was not seen among the obese subjects. However, as obesity is a common risk factor for both GER and lower FEV 1 , 23 it could be indicative of an actual relationship between nGER and lower FEV 1 to see this association in the normal weight subjects of our study population. This is not the first study to find a decrease in the pulmonary function of GER or nGER patients, although arguably the largest one until now. A study of US military veterans with reflux esophagitis found COPD, as well as many other respiratory diseases, to be more common than in a comparable control group. 24 Mise et al. found a significant decrease in FEV 1 and PEF in 32 patients with GER, as well as a lower pH and higher lactate dehydrogenase in bronchoalveolar aspirates, indicative of tissue damage. 6 In addition, patients with erosive GER disease have been found to have worse pulmonary function than those with non-erosive GER disease. 25 Symptoms of chronic bronchitis and asthma were more common in nGER subjects than in those without GER. This is in accordance with results from other studies, which show an association of GER with chronic cough, asthma and various upper respiratory tract symptoms. 2, 9, 24, 26 The before mentioned findings of Mise et al. further support possible causal relationships in these associations, but even so, they need to be studied further. 6 Our study shows that the nGER group had more OSA symptoms and more often symptoms of excessive daytime sleepiness than the "no nGER" group, even after adjusting for common risk factors such as obesity. This is in agreement with most former studies. 9, 11, 27, 28 One notable finding we have not seen reported before was the stronger association between OSA symptoms and nGER among women than men, even after the common adjustments. We were Figure 2 Comparison between the study groups regarding any respiratory or OSA symptom. Table 3 Multiple logistic regression on any respiratory symptom and any OSA symptom between GER groups, center, age, gender, smoking history and BMI (data on center omitted).
Any respiratory symptom (OR (95% CI)) p-value Any OSA symptom (OR (95% CI)) p-value not able to identify any obvious explanation for this gender difference.
There is an ongoing debate whether GER and OSA are causally linked. Some have pointed out that since obesity is a common risk factor for OSA and GER and the two conditions are rather common, it can be difficult to prove an association between the two conditions. 29 Also, impaired quality of sleep and daytime sleepiness can be caused by both OSA and nGER, making the differential diagnosis more complicated. 27 However, nasal CPAP treatment for OSA also significantly reduces the occurrence of nGER, supportive of an actual association between OSA and nGER. 10, 11 Also, other symptoms more specific of OSA, such as apneas, are more common in patients with nGER, as our study has shown. We therefore interpret our results as a further indication of a close association between nGER and OSA.
In the present cross-sectional analysis sleep-related and respiratory symptoms as well as COPD were less common in subjects with treated GER than the nGER group, thus indicating that GER medication might be beneficial against respiratory symptoms and sleep impairments in nGER patients. Other studies have shown mixed results as to whether or not medical GER treatment is beneficial for patients with GER-related respiratory symptoms. 26, 30, 31 However, the endpoints have differed between studies, as well as methods and study time. A review by Coughlan et al. on GER treatment in adult asthmatics implies that GER treatment has little effect on their respiratory illness. 31 However, more than half of the studies in this review had a treatment period of six weeks or less, and therefore it is not surprising the benefit was small. In fact, the studies with a longer treatment time showed more benefit than the others. As GER is usually a chronic condition with high prevalence and low incidence, 32 we can assume a large proportion of those on GER treatment in our study have been so for at least a few months. This might explain the positive trend of our study, regarding the efficacy of treatment. Further randomized controlled trials with longer treatment time are therefore needed before any definitive conclusions can be made on this subject.
The key strengths of this study were the high number of participants and the relatively high response rate. The quality of the post-bronchodilator spirometries, carried out by specially trained professionals, further increased the quality of this study. Even so, a few methodological issues need to be discussed. First, our definition of the nGER groups was based on self-reported heartburn, which has up to 80% sensitivity and 60% specificity, 1,33 but isn't diagnostic. To minimize the incidence of false positive values resulting from this, we therefore confined ourselves to those reporting heartburn at least once a week, which is generally accepted as a reasonably specific marker for GER disease. 32, 34 Second, the analysis of OSA symptoms is only based on subjective measurements, while the analysis of respiratory illnesses is based on objective measurements as well. Therefore, the analysis on OSA symptoms is somewhat weaker. Third, the definition of GER treatment might be too loose, since it does not differentiate between regular or p.n. usage, or between different types of medications. Therefore, subjects on minimal treatment were categorized as having GER treatment, increasing the number of subjects in the treated GER group. However, this also served to purify the group without GER, making it a better reference group.
Fourth, the use of two languages carries the risk of a translation bias. However, we consider this risk to be small, as the questions were all checked via backtranslation and tested for translation bias. The questions regarding nGER were based on a former, thoroughly validated questionnaire. 9 Finally, when studying many variables as in this study, the risk of a type I error must be considered. However, since there is a trend in the many positive results, where the symptom prevalence increased in the study groups similarly for various symptoms, the risk of a type I error must be considered small.
The results of this study suggested that nGER may be of clinical relevance in patients with OSA and in patients with respiratory symptoms. The evident decrease in pulmonary function associated with nGER also calls out for further studies on the association, and on the role of antireflux therapy in this context.
